SNDX

Syndax Pharmaceuticals, Inc.

Price Chart

Latest Quote

$19.00

-0.04 (-0.21%)

Current Price

Previous Close	$19.04
Open	$19.60
Day High	$20.37
Day Low	$18.93
Volume	3,994,857

Fetched: 2026-06-20T00:43:38

Stock Information

Shares Outstanding	88.61M
Total Debt	$345.36M
Cash Equivalents	$361.24M
Revenue	$217.17M
Net Income	$-243.25M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$1.68B
EPS (TTM)	$-2.79
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$1.63B
Sales	$217.17M
Income	$-243.25M
Book/sh	$0.47
Cash/sh	$4.08
Employees	298

Financial Ratios

Quick Ratio	4.90
Current Ratio	5.47
Debt/Eq	829.75

Returns & Margins

ROA	-25.12%
ROE	-189.53%
Gross Margin	-23.17%
Operating Margin	-52.73%
Profit Margin	-112.01%

Ownership

Insider Ownership	1.70%
Institutional Ownership	115.99%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-34.88
P/S	7.75
P/B	40.43

Analyst Data

Recommendation	strong_buy
Target Price	$39.00

Technical Indicators

SMA20	$18.65
SMA50	$20.46
SMA200	$19.50
RSI	44.06
ATR	0.8442

Shares Float	79.57M
Short Float	19.10%
Short Ratio	10.02
Volatility	0.39
Rel Volume	2.07

Performance History

Week	+6.09%
Month	-1.86%
Quarter	-20.83%
6 Months	-8.30%
YTD	-10.80%
Year	+97.10%
3 Years	-14.84%
5 Years	+1.28%
10 Years	+51.39%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$19.00	3,994,900
2026-06-17	$19.04	1,900,500
2026-06-16	$18.55	2,166,900
2026-06-15	$18.48	1,952,700
2026-06-12	$18.25	1,048,600
2026-06-11	$17.91	1,579,400
2026-06-10	$17.58	1,395,400
2026-06-09	$17.69	1,435,500
2026-06-08	$16.96	2,338,400
2026-06-05	$17.34	2,702,300
2026-06-04	$18.02	7,795,900
2026-06-03	$18.34	1,249,500
2026-06-02	$18.39	1,361,200
2026-06-01	$18.85	1,492,700
2026-05-29	$19.59	861,500
2026-05-28	$19.75	1,017,400
2026-05-27	$19.61	1,051,800
2026-05-26	$19.90	850,100
2026-05-22	$19.94	1,146,100
2026-05-21	$19.77	1,205,000
2026-05-20	$20.13	1,028,400
2026-05-19	$19.36	930,100

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

📰 Latest News

Syndax Pharmaceuticals (SNDX) Is Up 5.2% After Strong All-Oral Revuforj SAVE Trial Data - What's Changed

Simply Wall St. • 2026-06-13T12:12:08Z

Assessing Whether Syndax Pharmaceuticals (SNDX) Looks Undervalued After Recent Share Price Weakness

Simply Wall St. • 2026-05-24T08:10:40Z

Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential

Insider Monkey • 2026-05-14T16:50:49Z

Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain Traction - What’s Really Shifting?

Simply Wall St. • 2026-05-01T23:12:38Z

Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com • 2026-05-01T07:18:28Z

Syndax Pharmaceuticals Q1 Earnings Call Highlights

MarketBeat • 2026-05-01T02:42:05Z

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

Zacks • 2026-04-30T21:30:05Z

This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset

Motley Fool • 2026-03-22T00:20:02Z

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding

Motley Fool • 2026-03-21T22:43:15Z

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

Motley Fool • 2026-03-21T22:33:31Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$6,970,000	$826,000	$0	$0
Cost Of Revenue	$6,970,000	$826,000	$0	$0
Total Revenue	$172,352,000	$23,680,000	$0	$0
Operating Revenue	$172,352,000	$23,680,000	$0	$0
Expenses
Interest Expense	$33,785,000	$4,930,000	$208,000	$3,137,000
Total Expenses	$445,436,000	$363,352,000	$229,954,000	$151,757,000
Other Income Expense	$-1,283,000	$-247,000	$-361,000	$-316,000
Other Non Operating Income Expenses	$-1,283,000	$-247,000	$-361,000	$-316,000
Net Non Operating Interest Income Expense	$-11,055,000	$21,161,000	$20,955,000	$2,735,000
Interest Expense Non Operating	$33,785,000	$4,930,000	$208,000	$3,137,000
Operating Expense	$438,466,000	$362,526,000	$229,954,000	$151,757,000
General And Administrative Expense	$179,682,000	$120,879,000	$66,922,000	$33,258,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-285,422,000	$-318,758,000	$-209,360,000	$-149,338,000
Net Interest Income	$-11,055,000	$21,161,000	$20,955,000	$2,735,000
Interest Income	$22,730,000	$26,091,000	$21,163,000	$5,872,000
Normalized Income	$-285,422,000	$-318,758,000	$-209,360,000	$-149,338,000
Net Income From Continuing And Discontinued Operation	$-285,422,000	$-318,758,000	$-209,360,000	$-149,338,000
Total Operating Income As Reported	$-273,084,000	$-339,672,000	$-229,954,000	$-151,757,000
Net Income Common Stockholders	$-285,422,000	$-318,758,000	$-209,360,000	$-149,338,000
Net Income	$-285,422,000	$-318,758,000	$-209,360,000	$-149,338,000
Net Income Including Noncontrolling Interests	$-285,422,000	$-318,758,000	$-209,360,000	$-149,338,000
Net Income Continuous Operations	$-285,422,000	$-318,758,000	$-209,360,000	$-149,338,000
Pretax Income	$-285,422,000	$-318,758,000	$-209,360,000	$-149,338,000
Interest Income Non Operating	$22,730,000	$26,091,000	$21,163,000	$5,872,000
Operating Income	$-273,084,000	$-339,672,000	$-229,954,000	$-151,757,000
Gross Profit	$165,382,000	$22,854,000	$0	$0
Per Share
Diluted EPS	$-3.29	$-3.72	$-2.98	$-2.46
Basic EPS	$-3.29	$-3.72	$-2.98	$-2.46
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-251,631,000	$-313,820,000	$-209,140,000	$-146,168,000
Reconciled Depreciation	$6,000	$8,000	$12,000	$33,000
EBITDA (Bullshit earnings)	$-251,631,000	$-313,820,000	$-209,140,000	$-146,168,000
EBIT	$-251,637,000	$-313,828,000	$-209,152,000	$-146,201,000
Diluted Average Shares	$86,625,610	$85,622,065	$70,370,519	$60,760,906
Basic Average Shares	$86,625,610	$85,622,065	$70,370,519	$60,760,906
Diluted NI Availto Com Stockholders	$-285,422,000	$-318,758,000	$-209,360,000	$-149,338,000
Research And Development	$258,784,000	$241,647,000	$163,032,000	$118,499,000
Selling General And Administration	$179,682,000	$120,879,000	$66,922,000	$33,258,000
Other Gand A	$76,940,000	$50,894,000	$27,220,000	$33,258,000
Salaries And Wages	$102,742,000	$69,985,000	$39,702,000	-
Otherunder Preferred Stock Dividend	-	-	-	$0

Fetched: 2026-06-20

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$64,630,000	$288,124,000	$554,196,000	$467,449,000
Total Assets	$529,706,000	$724,816,000	$612,880,000	$497,236,000
Total Non Current Assets	$1,625,000	$121,759,000	$32,004,000	$7,450,000
Other Non Current Assets	$102,000	$217,000	$680,000	$922,000
Investmentin Financial Assets	$0	$119,520,000	$29,829,000	-
Current Assets	$528,081,000	$603,057,000	$580,876,000	$489,786,000
Other Current Assets	$1,219,000	$612,000	$63,000	$117,000
Prepaid Assets	$10,131,000	$5,295,000	$2,003,000	$1,215,000
Inventory	$32,754,000	$366,000	$0	-
Receivables	$70,291,000	$13,871,000	$1,227,000	$4,057,000
Other Receivables	$30,149,000	$3,635,000	-	-
Accrued Interest Receivable	$2,146,000	$2,634,000	$1,227,000	$583,000
Accounts Receivable	$37,996,000	$7,602,000	$0	$3,474,000
Cash Cash Equivalents And Short Term Investments	$413,686,000	$582,913,000	$577,583,000	$484,397,000
Cash And Cash Equivalents	$134,930,000	$154,083,000	$295,394,000	$74,356,000
Cash Equivalents	$134,930,000	$154,083,000	$295,394,000	$74,356,000
Restricted Cash	-	-	-	$0
Notes Receivable	-	-	-	$3,474,000
Debt
Net Debt	$208,979,000	$189,598,000	-	-
Total Debt	$345,432,000	$345,739,000	$1,635,000	$1,161,000
Long Term Debt And Capital Lease Obligation	$344,960,000	$333,143,000	$588,000	$722,000
Long Term Debt	$343,909,000	$331,565,000	-	-
Current Debt And Capital Lease Obligation	$472,000	$12,596,000	$1,047,000	$439,000
Current Debt	-	$12,116,000	-	-
Other Current Borrowings	-	$12,116,000	-	-
Liabilities
Total Liabilities Net Minority Interest	$465,076,000	$436,692,000	$58,684,000	$29,787,000
Total Non Current Liabilities Net Minority Interest	$344,960,000	$333,143,000	$588,000	$722,000
Current Liabilities	$120,116,000	$103,549,000	$58,096,000	$29,065,000
Other Current Liabilities	$10,531,000	$1,270,000	$888,000	$604,000
Payables And Accrued Expenses	$84,761,000	$75,206,000	$44,989,000	$22,077,000
Interest Payable	$25,516,000	$4,930,000	$0	-
Payables	$23,952,000	$31,164,000	$17,193,000	$4,350,000
Other Payable	$7,372,000	$19,538,000	$7,232,000	-
Accounts Payable	$16,580,000	$11,626,000	$9,961,000	$4,350,000
Non Current Deferred Liabilities	-	-	-	-
Current Deferred Liabilities	-	-	-	-
Equity
Common Stock Equity	$64,630,000	$288,124,000	$554,196,000	$467,449,000
Total Equity Gross Minority Interest	$64,630,000	$288,124,000	$554,196,000	$467,449,000
Stockholders Equity	$64,630,000	$288,124,000	$554,196,000	$467,449,000
Gains Losses Not Affecting Retained Earnings	$452,000	$163,000	$218,000	$-806,000
Other Equity Adjustments	$452,000	$163,000	$218,000	$-806,000
Retained Earnings	$-1,506,580,000	$-1,221,158,000	$-902,400,000	$-693,040,000
Other
Ordinary Shares Number	$87,405,979	$85,694,443	$84,826,632	$68,111,385
Share Issued	$87,405,979	$85,694,443	$84,826,632	$68,111,385
Tangible Book Value	$64,630,000	$288,124,000	$554,196,000	$467,449,000
Invested Capital	$408,539,000	$631,805,000	$554,196,000	$467,449,000
Working Capital	$407,965,000	$499,508,000	$522,780,000	$460,721,000
Capital Lease Obligations	$1,523,000	$2,058,000	$1,635,000	$1,161,000
Total Capitalization	$408,539,000	$619,689,000	$554,196,000	$467,449,000
Additional Paid In Capital	$1,570,749,000	$1,509,110,000	$1,456,370,000	$1,161,288,000
Capital Stock	$9,000	$9,000	$8,000	$7,000
Common Stock	$9,000	$9,000	$8,000	$7,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$1,051,000	$1,578,000	$588,000	$722,000
Current Capital Lease Obligation	$472,000	$480,000	$1,047,000	$439,000
Pensionand Other Post Retirement Benefit Plans Current	$24,352,000	$14,477,000	$11,172,000	$5,945,000
Current Accrued Expenses	$60,809,000	$44,042,000	$27,796,000	$17,727,000
Investments And Advances	$0	$119,520,000	$29,829,000	$5,469,000
Net PPE	$1,523,000	$2,022,000	$1,495,000	$1,059,000
Accumulated Depreciation	$-425,000	$-419,000	$-411,000	$-399,000
Gross PPE	$1,948,000	$2,441,000	$1,906,000	$1,458,000
Leases	$167,000	$167,000	$167,000	$167,000
Other Properties	$1,613,000	$2,106,000	$1,571,000	$1,123,000
Machinery Furniture Equipment	$168,000	$168,000	$168,000	$168,000
Properties	$0	$0	$0	$0
Finished Goods	$1,615,000	$36,000	$0	-
Work In Process	$2,112,000	$330,000	$0	-
Raw Materials	$29,027,000	$0	$0	-
Other Short Term Investments	$278,756,000	$428,830,000	$282,189,000	$410,041,000
Available For Sale Securities	-	$119,520,000	$29,829,000	-
Non Current Deferred Revenue	-	-	-	-
Current Deferred Revenue	-	-	-	-

Fetched: 2026-06-20

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-323,167,000	$-274,903,000	$-160,601,000	$-133,675,000
Operating Activities
Operating Cash Flow	$-322,980,000	$-274,903,000	$-160,601,000	$-133,675,000
Cash Flow From Continuing Operating Activities	$-322,980,000	$-274,903,000	$-160,601,000	$-133,675,000
Operating Gains Losses	-	-	-	$-187,000
Investing Activities
Capital Expenditure	$-187,000	-	-	-
Investing Cash Flow	$290,036,000	$-219,775,000	$117,609,000	$-186,188,000
Cash Flow From Continuing Investing Activities	$290,036,000	$-219,775,000	$117,609,000	$-186,188,000
Financing Activities
Issuance Of Capital Stock	$0	$0	$258,094,000	$181,390,000
Financing Cash Flow	$13,676,000	$353,367,000	$264,132,000	$172,254,000
Cash Flow From Continuing Financing Activities	$13,676,000	$353,367,000	$264,132,000	$172,254,000
Net Common Stock Issuance	$0	$0	$258,094,000	$181,390,000
Common Stock Issuance	$0	$0	$258,094,000	$181,390,000
Net Other Financing Charges	-	$343,652,000	-	-
Other
Interest Paid Supplemental Data	$13,191,000	$0	$0	$2,059,000
End Cash Position	$135,032,000	$154,300,000	$295,611,000	$74,471,000
Beginning Cash Position	$154,300,000	$295,611,000	$74,471,000	$222,080,000
Changes In Cash	$-19,268,000	$-141,311,000	$221,140,000	$-147,609,000
Proceeds From Stock Option Exercised	$13,676,000	$9,715,000	$6,038,000	$11,860,000
Net Investment Purchase And Sale	$290,223,000	$-219,775,000	$117,609,000	$-186,413,000
Sale Of Investment	$486,030,000	$337,277,000	$472,215,000	$308,933,000
Purchase Of Investment	$-195,807,000	$-557,052,000	$-354,606,000	$-495,346,000
Net PPE Purchase And Sale	$-187,000	$0	$0	$225,000
Purchase Of PPE	$-187,000	$0	$0	$0
Change In Working Capital	$-79,318,000	$13,270,000	$31,860,000	$1,656,000
Change In Other Current Assets	$0	$463,000	$0	$0
Change In Payables And Accrued Expense	$47,121,000	$20,804,000	$20,478,000	$8,102,000
Change In Accrued Expense	$42,167,000	$19,139,000	$14,867,000	$9,421,000
Change In Payable	$4,954,000	$1,665,000	$5,611,000	$-1,319,000
Change In Account Payable	$4,954,000	$1,665,000	$5,611,000	$-1,319,000
Change In Prepaid Assets	$-14,542,000	$-8,393,000	$676,000	$-2,972,000
Change In Inventory	$-32,091,000	$-366,000	$0	$0
Change In Receivables	$-79,806,000	$762,000	$10,706,000	$0
Changes In Account Receivables	$-30,394,000	$-7,602,000	$0	$0
Other Non Cash Items	$1,337,000	$1,019,000	$739,000	$1,524,000
Stock Based Compensation	$47,503,000	$43,026,000	$30,951,000	$16,019,000
Provisionand Write Offof Assets	$3,667,000	$0	$0	-
Amortization Of Securities	$-10,753,000	$-13,468,000	$-14,803,000	$-3,382,000
Depreciation Amortization Depletion	$6,000	$8,000	$12,000	$33,000
Depreciation And Amortization	$6,000	$8,000	$12,000	$33,000
Depreciation	$6,000	$8,000	$12,000	$33,000
Net Income From Continuing Operations	$-285,422,000	$-318,758,000	$-209,360,000	$-149,338,000
Repayment Of Debt	-	$0	$0	$-20,996,000
Net Issuance Payments Of Debt	-	$0	$0	$-20,996,000
Net Long Term Debt Issuance	-	$0	$0	$-20,996,000
Long Term Debt Payments	-	$0	$0	$-20,996,000
Sale Of PPE	-	$0	$0	$225,000
Change In Other Working Capital	-	$11,999,000	$10,706,000	$-3,474,000
Issuance Of Debt	-	-	-	$0
Long Term Debt Issuance	-	-	-	$0
Gain Loss On Investment Securities	-	-	-	$-187,000

Fetched: 2026-06-20